PUBLISHER: The Business Research Company | PRODUCT CODE: 1957840
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957840
Synthetic hormones are man-made substances designed to imitate the action of natural hormones in the body. These hormones are usually produced through chemical synthesis instead of being obtained from natural sources and are employed in medical treatments to control different physiological processes or to substitute hormones that the body may not generate in adequate amounts.
The main types of synthetic hormones include steroid hormones, peptide hormones, amino acid derivatives, and others. Steroid hormones are a group of hormones derived from cholesterol and are characterized by a structure that contains four interconnected carbon rings. Different routes of administration include oral, nasal, topical, and intravenous methods. Their applications cover growth hormone deficiency, thyroid hormone deficiency, menopause, male hypogonadism, and others, and they are used by various end users such as hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have affected the synthetic hormones market by increasing the cost of raw materials and chemical intermediates used in production, particularly impacting steroid and peptide hormone segments. Regions such as North America and Europe, which rely heavily on imports for active pharmaceutical ingredients (APIs), are most affected. The tariffs have led manufacturers to explore local sourcing, optimize supply chains, and innovate cost-efficient formulations. In some cases, higher tariffs have also encouraged domestic production, providing a potential positive impact on regional manufacturing capabilities.
The synthetic hormones market research report is one of a series of new reports from The Business Research Company that provides synthetic hormones market statistics, including synthetic hormones industry global market size, regional shares, competitors with a synthetic hormones market share, detailed synthetic hormones market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic hormones industry. This synthetic hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The synthetic hormones market size has grown steadily in recent years. It will grow from $6.71 billion in 2025 to $7 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to advancements in chemical synthesis, increasing prevalence of hormonal disorders, rising awareness of hormone replacement therapy, expansion of hospital and retail pharmacy networks, early adoption of insulin and growth hormones.
The synthetic hormones market size is expected to see steady growth in the next few years. It will grow to $8.34 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to integration of ai in hormone therapy, development of oral and non-invasive hormone delivery, growth in personalized medicine, expansion of online pharmacy platforms, innovation in peptide and amino acid derivative hormones. Major trends in the forecast period include personalized hormone therapy development, advanced drug delivery systems, synthetic hormone formulation innovation, growth in hormone replacement therapy adoption, regulatory compliance and quality standards.
The increasing prevalence of hormonal imbalances is expected to drive the growth of the synthetic hormones market in the coming years. Hormonal imbalances arise when the body produces excessive or insufficient amounts of certain hormones, resulting in disruptions caused by aging, stress, lifestyle factors, or underlying medical conditions. These imbalances often necessitate therapeutic intervention, and synthetic hormones play a crucial role by supplementing or replacing deficient hormones to restore normal physiological function and relieve associated symptoms. The rising demand for hormone replacement therapy (HRT) reflects the growing occurrence of these conditions. For example, in January 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, polycystic ovary syndrome is a major public health issue and one of the most common hormonal disorders among women of reproductive age, affecting an estimated 6-13% of women, with up to 70% of cases remaining undiagnosed. Consequently, the increasing prevalence of hormonal imbalances is fueling the growth of the synthetic hormones market.
Major companies in the synthetic hormone market are concentrating on developing innovative biosimilar formulations, such as high-concentration recombinant human growth hormone (rhGH), to address the growing demand for more accessible and affordable treatments for growth-hormone deficiency and short stature. High-concentration rhGH refers to a type of synthetic growth hormone (typically somatropin) produced using recombinant DNA technology, with an increased drug content per volume, enabling smaller injection volumes, greater convenience, and potentially improved treatment adherence compared to conventional lower-concentration formulations. For example, in May 2025, Sandoz AG, a Switzerland-based leader in generics and biosimilars, introduced OMNITROPE in a new 15 mg / 1.5 mL concentration for the Egyptian market. This formulation contains somatropin produced via recombinant DNA technology in bacteria, is functionally equivalent to human endogenous growth hormone, and is provided in a more concentrated form to reduce injection burden and limit treatment interruptions; it is indicated for pediatric short stature (e.g., in Turner syndrome, small-for-gestational-age children, Prader-Willi syndrome) and adult GH deficiency, and is priced to increase access under Egypt's Vision 2030 public-health initiative.
In November 2023, Aspen Pharmacare Holdings Limited, a South Africa-based pharmaceutical company, acquired Sandoz's Chinese business for $100 million. This acquisition includes Sandoz's China operations, which offer products such as the synthetic hormone injectable Sandostatin. This strategic move enables Aspen to expand its presence and capabilities in China's pharmaceutical market. Sandoz (China) Pharmaceutical Co., Ltd. is a China-based pharmaceutical company that provides a variety of pharmaceutical products, including synthetic hormones.
Major companies operating in the synthetic hormones market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb Company, Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd., Ferring B.V., Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., IBSA Institute Biochimique SA, American Regent Inc., McGuff Pharmaceuticals Inc., Anhui Anke Biotechnology Co.Ltd, Acerus Pharmaceuticals Corporation, Slayback Pharma LLC
North America was the largest region in the synthetic hormones market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the synthetic hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the synthetic hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The synthetic hormones market consists of sales of anabolic steroids, insulin, oral contraceptives, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Synthetic Hormones Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses synthetic hormones market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for synthetic hormones ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The synthetic hormones market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.